mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines
The advent of the Omicron variant globally has hastened the requirement for a booster vaccination dose to confer continuous protection against symptomatic SARS-CoV2 infection. However, different vaccines are available in different countries, and individuals who had adverse reactions to certain vacci...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/7/1057 |
| _version_ | 1797433045788131328 |
|---|---|
| author | Biyan Zhang Jianxin Huo Yuhan Huang Shuan Yong Teo Kaibo Duan Yanfeng Li Lim Kai Toh Kong Peng Lam Shengli Xu |
| author_facet | Biyan Zhang Jianxin Huo Yuhan Huang Shuan Yong Teo Kaibo Duan Yanfeng Li Lim Kai Toh Kong Peng Lam Shengli Xu |
| author_sort | Biyan Zhang |
| collection | DOAJ |
| description | The advent of the Omicron variant globally has hastened the requirement for a booster vaccination dose to confer continuous protection against symptomatic SARS-CoV2 infection. However, different vaccines are available in different countries, and individuals who had adverse reactions to certain vaccine types require heterologous vaccine boosters. To understand the efficacy of different vaccination regimens in inducing humoral responses to SARS-CoV2, we examined plasma antibodies and frequencies of Omicron RBD-specific B cells in individuals who had different priming-booster vaccination regimens. We found that individuals with three homologous doses of mRNA vaccines had higher levels of IgG of all subclasses against RBD of Omicron than individuals with three homologous doses of inactivated virus vaccine. A booster with mRNA vaccine resulted in significant increases in median levels of RBD-reactive IgG1 (17–19 fold) and IgG3 (2.3–3.3 fold) as compared to individuals receiving inactivated virus booster shots regardless of priming vaccine types. More importantly, individuals who received a booster dose of mRNA vaccine, irrespective of the priming vaccine, had antibodies with higher neutralizing capability against the Omicron variant than those who received a booster dose of inactivated virus vaccine. Corroborating the antibody results, boosting with the mRNA vaccine increased the frequencies of Omicron RBD-binding B cells by (1.5–3.3 fold) regardless of priming vaccine types. Together, our data demonstrate that an mRNA vaccine (BNT162b2 or mRNA-1273) booster enhances humoral responses against the Omicron variant in individuals vaccinated with either two prior doses of mRNA or inactivated virus vaccine (CoronaVac or BBIBP-CorV), potentially providing more effective protection against SARS-CoV-2 infection, particularly by the Omicron variant. |
| first_indexed | 2024-03-09T10:10:26Z |
| format | Article |
| id | doaj.art-7087cf598dbe4cd4bef79e323bea4c18 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T10:10:26Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-7087cf598dbe4cd4bef79e323bea4c182023-12-01T22:46:14ZengMDPI AGVaccines2076-393X2022-06-01107105710.3390/vaccines10071057mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus VaccinesBiyan Zhang0Jianxin Huo1Yuhan Huang2Shuan Yong Teo3Kaibo Duan4Yanfeng Li5Lim Kai Toh6Kong Peng Lam7Shengli Xu8Singapore Immunology Network, Agency for Science, Technology and Research, 8A Biomedical Grove, Singapore 138648, SingaporeSingapore Immunology Network, Agency for Science, Technology and Research, 8A Biomedical Grove, Singapore 138648, SingaporeSingapore Immunology Network, Agency for Science, Technology and Research, 8A Biomedical Grove, Singapore 138648, SingaporeSingapore Immunology Network, Agency for Science, Technology and Research, 8A Biomedical Grove, Singapore 138648, SingaporeSingapore Immunology Network, Agency for Science, Technology and Research, 8A Biomedical Grove, Singapore 138648, SingaporeGenscript, 164 Kallang Way, East Wing, #06-12, Singapore 349248, SingaporeDoctors for Life Medical, 03 Pickering Street, #01-02, Nankin Row, Singapore 048660, SingaporeSingapore Immunology Network, Agency for Science, Technology and Research, 8A Biomedical Grove, Singapore 138648, SingaporeSingapore Immunology Network, Agency for Science, Technology and Research, 8A Biomedical Grove, Singapore 138648, SingaporeThe advent of the Omicron variant globally has hastened the requirement for a booster vaccination dose to confer continuous protection against symptomatic SARS-CoV2 infection. However, different vaccines are available in different countries, and individuals who had adverse reactions to certain vaccine types require heterologous vaccine boosters. To understand the efficacy of different vaccination regimens in inducing humoral responses to SARS-CoV2, we examined plasma antibodies and frequencies of Omicron RBD-specific B cells in individuals who had different priming-booster vaccination regimens. We found that individuals with three homologous doses of mRNA vaccines had higher levels of IgG of all subclasses against RBD of Omicron than individuals with three homologous doses of inactivated virus vaccine. A booster with mRNA vaccine resulted in significant increases in median levels of RBD-reactive IgG1 (17–19 fold) and IgG3 (2.3–3.3 fold) as compared to individuals receiving inactivated virus booster shots regardless of priming vaccine types. More importantly, individuals who received a booster dose of mRNA vaccine, irrespective of the priming vaccine, had antibodies with higher neutralizing capability against the Omicron variant than those who received a booster dose of inactivated virus vaccine. Corroborating the antibody results, boosting with the mRNA vaccine increased the frequencies of Omicron RBD-binding B cells by (1.5–3.3 fold) regardless of priming vaccine types. Together, our data demonstrate that an mRNA vaccine (BNT162b2 or mRNA-1273) booster enhances humoral responses against the Omicron variant in individuals vaccinated with either two prior doses of mRNA or inactivated virus vaccine (CoronaVac or BBIBP-CorV), potentially providing more effective protection against SARS-CoV-2 infection, particularly by the Omicron variant.https://www.mdpi.com/2076-393X/10/7/1057vaccinesSARS-CoV-2omicronboosterantibodiesB cells |
| spellingShingle | Biyan Zhang Jianxin Huo Yuhan Huang Shuan Yong Teo Kaibo Duan Yanfeng Li Lim Kai Toh Kong Peng Lam Shengli Xu mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines Vaccines vaccines SARS-CoV-2 omicron booster antibodies B cells |
| title | mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines |
| title_full | mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines |
| title_fullStr | mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines |
| title_full_unstemmed | mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines |
| title_short | mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines |
| title_sort | mrna booster vaccination enhances antibody responses against sars cov2 omicron variant in individuals primed with mrna or inactivated virus vaccines |
| topic | vaccines SARS-CoV-2 omicron booster antibodies B cells |
| url | https://www.mdpi.com/2076-393X/10/7/1057 |
| work_keys_str_mv | AT biyanzhang mrnaboostervaccinationenhancesantibodyresponsesagainstsarscov2omicronvariantinindividualsprimedwithmrnaorinactivatedvirusvaccines AT jianxinhuo mrnaboostervaccinationenhancesantibodyresponsesagainstsarscov2omicronvariantinindividualsprimedwithmrnaorinactivatedvirusvaccines AT yuhanhuang mrnaboostervaccinationenhancesantibodyresponsesagainstsarscov2omicronvariantinindividualsprimedwithmrnaorinactivatedvirusvaccines AT shuanyongteo mrnaboostervaccinationenhancesantibodyresponsesagainstsarscov2omicronvariantinindividualsprimedwithmrnaorinactivatedvirusvaccines AT kaiboduan mrnaboostervaccinationenhancesantibodyresponsesagainstsarscov2omicronvariantinindividualsprimedwithmrnaorinactivatedvirusvaccines AT yanfengli mrnaboostervaccinationenhancesantibodyresponsesagainstsarscov2omicronvariantinindividualsprimedwithmrnaorinactivatedvirusvaccines AT limkaitoh mrnaboostervaccinationenhancesantibodyresponsesagainstsarscov2omicronvariantinindividualsprimedwithmrnaorinactivatedvirusvaccines AT kongpenglam mrnaboostervaccinationenhancesantibodyresponsesagainstsarscov2omicronvariantinindividualsprimedwithmrnaorinactivatedvirusvaccines AT shenglixu mrnaboostervaccinationenhancesantibodyresponsesagainstsarscov2omicronvariantinindividualsprimedwithmrnaorinactivatedvirusvaccines |